Please check your internet connection and try again.
# Ticagrelor (Brilinta)
## Overview
Ticagrelor is a P2Y12 platelet inhibitor used to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). It is a direct-acting, reversible binding agent.
## Primary Indications
* Treatment of acute coronary syndrome (ACS).
* Prevention of thrombotic events in patients with a history of MI.
## Adult Dosing
* **ACS:** A 300 mg loading dose on day 1, followed by 90 mg twice daily for up to 12 months. In some cases, 60 mg twice daily may be considered for longer durations based on individual risk assessment.
* **History of MI:** 60 mg twice daily.
## Pediatric Dosing
Dosing for pediatric patients is not established.
## Dose Adjustments
No dose adjustments are necessary for patients with hepatic or renal impairment.
## Contraindications
* Active pathological bleeding.
* History of intracranial hemorrhage.
* Known hypersensitivity to ticagrelor or any component of the formulation.
## Adverse Effects
* **Major Bleeding:** This is the most significant risk. Includes fatal, intracranial, and gastrointestinal bleeding.
* **Dyspnea:** Common, often transient, and typically not associated with underlying pulmonary disease.
* **Bradycardia:** Can occur, especially within the first week of treatment.
* **Increased Creatinine:** Transient elevations may occur.
* **Gout:** May be exacerbated.
## Key Drug Interactions
* **CYP3A4 Substrates:** Ticagrelor is a moderate inhibitor of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase ticagrelor exposure. Conversely, strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may decrease ticagrelor exposure.
* **CYP3A4 Substrates (e.g., simvastatin, atorvastatin):** Ticagrelor can increase the plasma concentrations of these drugs, potentially increasing the risk of myopathy. Dose adjustments of these substrates may be necessary.
* **Other Antithrombotics:** Increased risk of bleeding when used with anticoagulants (e.g., warfarin, DOACs) or other antiplatelet agents.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor for dyspnea.
* Monitor renal function and electrolytes, particularly if there are other risk factors for renal impairment.
## Clinical Pearls
* Ticagrelor should be initiated as soon as possible in patients with ACS.
* It is important to instruct patients not to stop ticagrelor prematurely, as this can increase the risk of stent thrombosis or other thrombotic events. If a temporary interruption is necessary for surgery, weigh the risks and benefits carefully.
* Aspirin is typically continued indefinitely with ticagrelor in ACS patients, but the optimal dose of aspirin for long-term use in combination with ticagrelor is not definitively established and may vary by local protocol. Generally, a low-dose (e.g., 75-100 mg daily) is preferred after the initial treatment period.
* Ticagrelor is not a prodrug and does not require activation by CYP2C19, unlike clopidogrel.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making treatment decisions.*
